Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody that is approved for children ages 12 and older.
It is an injection that is indicated for Severe Asthma with an elevated eosinophil count.
It works by binding to IL-5 and blocking it from binding to the IL-5 receptor complex that is expressed on the eosinophil cell surface.
